[go: up one dir, main page]

MX2016000021A - Sirna virus especifico del dengue, estructura arn oligo helicoidal, y composicion para la supresion de proliferacion del virus del dengue que comprende la estructura arn. - Google Patents

Sirna virus especifico del dengue, estructura arn oligo helicoidal, y composicion para la supresion de proliferacion del virus del dengue que comprende la estructura arn.

Info

Publication number
MX2016000021A
MX2016000021A MX2016000021A MX2016000021A MX2016000021A MX 2016000021 A MX2016000021 A MX 2016000021A MX 2016000021 A MX2016000021 A MX 2016000021A MX 2016000021 A MX2016000021 A MX 2016000021A MX 2016000021 A MX2016000021 A MX 2016000021A
Authority
MX
Mexico
Prior art keywords
double helix
rna structure
sirna
dengue virus
rna
Prior art date
Application number
MX2016000021A
Other languages
English (en)
Inventor
Oh Park Han
Sung Yang Joo
Ja Choi Soon
Seok KIM Woo
Original Assignee
Bioneer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioneer Corp filed Critical Bioneer Corp
Publication of MX2016000021A publication Critical patent/MX2016000021A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un siRNA especifico del virus del dengue, una estructura oligo ARN bicatenario que comprende el siRNA, y una composición para inhibir la replica del virus del dengue, el cual comprende el mismo, en el que la estructura oligo ARN bicatenario comprende un compuesto hidrofilico y un compuesto hidrofóbico conjugado en ambos extremos del ARN bicatenario (siRNA) por medio de un enlace covalente simple o un enlace covalente mediado por un conector para que se entreguen de manera eficiente en las células, y se puedan convertir en nanoparticulas mediante interacciones hidrofóbicas entre las estructuras oligo ARN bicatenariasen una solución acuosa. El siRNA incluido eñ ña estructura oligo ARN bicatenario actúa de manera específica en todos los serotipos del virus del dengue. La presente invención también se refiere a un método para preparar una estructura oligo ARN bicatenario, y una composición farmacéutica para prevenir o tratar la infección del virus del dengue, la cual comprende la estructura oligo ARN bicatenario.
MX2016000021A 2013-07-05 2014-07-04 Sirna virus especifico del dengue, estructura arn oligo helicoidal, y composicion para la supresion de proliferacion del virus del dengue que comprende la estructura arn. MX2016000021A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130079310 2013-07-05
PCT/KR2014/006032 WO2015002512A1 (ko) 2013-07-05 2014-07-04 뎅기 바이러스 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 뎅기 바이러스 증식 억제용 조성물

Publications (1)

Publication Number Publication Date
MX2016000021A true MX2016000021A (es) 2017-04-06

Family

ID=52144017

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000021A MX2016000021A (es) 2013-07-05 2014-07-04 Sirna virus especifico del dengue, estructura arn oligo helicoidal, y composicion para la supresion de proliferacion del virus del dengue que comprende la estructura arn.

Country Status (10)

Country Link
US (1) US9695421B2 (es)
EP (1) EP3018210A4 (es)
JP (1) JP6368363B2 (es)
KR (1) KR101715228B1 (es)
CN (1) CN105705639A (es)
AU (1) AU2014284835B2 (es)
CA (1) CA2917318A1 (es)
MX (1) MX2016000021A (es)
SG (1) SG11201507571TA (es)
WO (1) WO2015002512A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3463406A4 (en) * 2016-06-01 2020-01-22 Excision Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING LYTICS AND LYSOGENIC VIRUSES
KR101888104B1 (ko) * 2016-10-12 2018-08-14 사회복지법인 삼성생명공익재단 MET 엑손 14 스키핑 특이적 siRNA 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물
KR101986188B1 (ko) 2017-07-12 2019-06-07 서울대학교산학협력단 Rna 의존성 rna 중합효소 활성 확인 방법 및 키트
KR102473989B1 (ko) * 2018-11-28 2022-12-07 (주)바이오니아 안드로젠 수용체 특이적 서열을 포함하는 이중나선 올리고뉴클레오티드 구조체, 및 이를 포함하는 탈모 예방 및 발모용 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
EP0692972B2 (en) 1993-04-02 2012-03-21 AntiCancer, Inc. Method for delivering beneficial compositions to hair follicles
US6277967B1 (en) 1998-07-14 2001-08-21 Isis Pharmaceuticals, Inc. Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
US6175001B1 (en) 1998-10-16 2001-01-16 The Scripps Research Institute Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same
EP1263965B1 (en) * 2000-02-16 2011-09-28 The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services Avirulent, immunogenic flavivirus chimeras
US20030224353A1 (en) * 2001-10-16 2003-12-04 Stein David A. Antisense antiviral agent and method for treating ssRNA viral infection
WO2004076664A2 (en) * 2003-02-21 2004-09-10 University Of South Florida Vectors for regulating gene expression
AU2004276226B2 (en) * 2003-08-05 2009-07-30 Avi Biopharma, Inc. Oligonucleotide analog and method for treating flavivirus infections
US7385049B2 (en) * 2003-11-12 2008-06-10 Bayer Healthcare Llc Oligonucleotides and methods for detection of West Nile virus
AU2005277547B2 (en) * 2004-08-16 2011-08-25 Immune Disease Institute, Inc. Method of delivering RNA interference and uses thereof
US20060078624A1 (en) 2004-09-29 2006-04-13 Samuel Zalipsky Microparticles and nanoparticles containing a lipopolymer
TWI386225B (zh) 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
CN101287835A (zh) * 2005-08-17 2008-10-15 株式会社百奥尼 用于siRNA细胞内输送的siRNA-亲水性聚合物结合物及其方法
WO2007044468A2 (en) * 2005-10-05 2007-04-19 The Cbr Institute For Biomedical Research, Inc. Method to treat flavivirus infection with sirna
JP2010507387A (ja) * 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
WO2008087643A2 (en) 2007-01-16 2008-07-24 Proteologics Ltd Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors
US9173840B2 (en) 2008-10-09 2015-11-03 Northeastern University Multifunctional self-assembling polymeric nanosystems
EP2414322B1 (en) * 2009-03-20 2022-09-14 Egen, Inc. Polyamine derivatives
KR101224828B1 (ko) 2009-05-14 2013-01-22 (주)바이오니아 ｓｉＲＮＡ 접합체 및 그 제조방법
US8569256B2 (en) * 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
AR078921A1 (es) 2009-11-09 2011-12-14 Hoffmann La Roche Composiciones y metodos para inhibir la expresion de genes de la superfamilia de quinesinas, kif10
US20110206617A1 (en) * 2010-02-22 2011-08-25 Krishnendu Roy Modified polysaccharides for drug and contrast agent delivery
WO2013012835A2 (en) * 2011-07-18 2013-01-24 Oregon Health & Science University Sirna useful in the treatment of flavivirus infection
GEP201706616B (en) 2011-07-29 2017-02-10 Karyopharm Therapeutics Inc Hydrazide containing nuclear transport modulators and usage thereof
DK2768958T3 (da) 2011-10-18 2019-09-16 Dicerna Pharmaceuticals Inc Kationiske aminlipider og anvendelser deraf
GB201119028D0 (en) * 2011-11-04 2011-12-14 Epistem Ltd Dengue assay
AU2012353058B2 (en) 2011-12-15 2015-05-21 Bioneer Corporation Novel oligonucleotide conjugates and use thereof
EP2801615B1 (en) 2012-01-05 2025-06-25 Bioneer Corporation High-efficiency nanoparticle-type double-helical oligo-rna structure and method for preparing same
KR101392973B1 (ko) 2012-10-15 2014-05-09 (주)바이오니아 ｓｉＲＮＡ 접합체 및 그 제조방법

Also Published As

Publication number Publication date
JP2016524901A (ja) 2016-08-22
CN105705639A (zh) 2016-06-22
EP3018210A4 (en) 2017-06-07
AU2014284835A1 (en) 2016-02-18
WO2015002512A1 (ko) 2015-01-08
US9695421B2 (en) 2017-07-04
SG11201507571TA (en) 2015-10-29
CA2917318A1 (en) 2015-01-08
KR101715228B1 (ko) 2017-03-13
KR20150143425A (ko) 2015-12-23
US20160145622A1 (en) 2016-05-26
JP6368363B2 (ja) 2018-08-01
EP3018210A1 (en) 2016-05-11
AU2014284835B2 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
CY1125368T1 (el) Εμβολια κατα των ιων του αναπνευστικου συστηματος
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
WO2015061294A3 (en) Use of sting agonists to treat chronic hepatitis b virus infection
MY169159A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
PH12018500856A1 (en) Respiratory syncytial virus vaccine
MX2022006603A (es) Vacuna contra el virus de la influenza de amplio espectro.
JP2012143233A5 (es)
EP4632068A3 (en) Materials and methods for treatment of duchenne muscular dystrophy
AR096113A1 (es) Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados
WO2016061232A3 (en) Multiplexed shrnas and uses thereof
MD4589B1 (ro) Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
PH12019500513A1 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
PH12015502230B1 (en) Novel viral replication inhibitors
MX383706B (es) Composiciones de cenicriviroc y métodos para elaborarlas y usarlas.
EA201592081A1 (ru) СОЕДИНЕНИЯ НА ОСНОВЕ МИКРО-РНК И СПОСОБЫ МОДУЛИРОВАНИЯ АКТИВНОСТИ miR-122
NZ603863A (en) Concentration and lyophilization of influenza vaccine antigens
MX359981B (es) Virus de sarampión recombinante que expresa polipéptidos del virus de chinkunguña, y sus aplicaciones.
PH12017500450A1 (en) Flavivirus virus like particle
PH12016500465A1 (en) Deoxynojirimycin derivatives and methods of their using
MX2016000021A (es) Sirna virus especifico del dengue, estructura arn oligo helicoidal, y composicion para la supresion de proliferacion del virus del dengue que comprende la estructura arn.
GB2544439A (en) Antiviral composition
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
AR095118A1 (es) Un procedimiento de inactivación viral en composición que comprende factor vii
EA201500694A1 (ru) Монолитная лекарственная форма для модифицированного высвобождения комбинации активных ингредиентов
EP2814498A4 (en) GUANOSOLE OLIGONUCLEOTIDE COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF RSV INFECTION